…Investigators in honor of his work to advance knowledge of BRCA1-mutant ovarian cancer in order to overcome treatment resistance. A panel composed of select members of OCRA’s Scientific Advisory Committee…
…participation, and brought patient research advocates together with pharmaceutical companies in an industry roundtable to share opportunities and challenges around this issue. Did you know we all have the BRCA gene? Find…
…taking letrozole and I’ve been in remission since! Do you have a genetic mutation associated with ovarian cancer? I am BRCA2 positive. My daughters are also BRCA2 positive, and they…
…our family history, it made sense for Barack and for me to get tested for the BRCA gene mutation, which can indicate risk for ovarian and breast cancer. Thankfully, we…
…particularly in identifying BRCA mutations and other genetic markers that guide treatment with precision therapies such as PARP inhibitors. Key findings of the OCRA analysis show that only 52% of…
The Supreme Court of the United States will hear arguments in a case seeking to invalidate the patents on the BRCA1 and BRCA2 mutations. The patent-holder, Myriad Laboratories, owns patents…
…models with BRCA1 or BRCA2 genetic mutations, and is effective even in tumors that have become resistant to PARP inhibitors. Found that a combination of CDK9 inhibition and PP2A activation…
…million genetic variants with epithelial ovarian cancer risk and found six additional susceptibility regions, bringing the total to 18. The variants identified have a less dramatic impact than BRCA1 or…
…to advance innovative treatment approaches for ovarian cancers involving mutations in the BRCA1 and BRCA2 genes. Dr. Verma’s independent lab integrates several cutting-edge genomics and molecular biology tools to study…
…DC, “Targeting Chromobox 2 to overcome macrophage-induced immune suppression” Sammy Ferri-Borgogno, PhD, University of Texas M.D. Anderson Cancer Center, “BRCA-deficient ovarian cancer and IFITM3: a new “power couple” Livnat Jerby,…
…2009 and diagnosed with breast cancer, ovarian cancer, or both. Within this population of 718 women, 92 of them were eligible for BRCA1 and BRCA2 testing but only eight of…
…PARP inhibitors, and even how genetic predispositions, such as BRCA1 and BRCA2 mutations, can change the trajectory of treatment. “Our goal to these two approaches,” Ie-Ming said, “is to convert…
Get email updates about research news, action alerts, and ways to join the fight.
